Skip to content

Observation on the efficacy of parecoxib Q12h analgesic drug and SOS regimen for intestinal function recovery after colorectal surgery

Observation on the efficacy of parecoxib Q12h analgesic drug and SOS regimen for intestinal function recovery after colorectal surgery

Status
Active, not recruiting
Phases
Phase 4
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR2000041184
Enrollment
Unknown
Registered
2020-12-20
Start date
2017-05-01
Completion date
Unknown
Last updated
2021-03-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Colorectal surgery

Interventions

1:Parecoxib
2:Normal saline

Sponsors

The First Affiliated Hospital of Harbin Medical University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 80 Years

Inclusion criteria

Inclusion criteria: (1) Colorectal surgery including radical resection of colorectal cancer, subtotal colectomy for chronic constipation and other laparoscopic and conventional open surgery is required after the diagnosis is clear. (2) The age is between 18 and 80 years old. (3) Ability to communicate in normal language (4) No movement disorder and no mood or mental cognitive impairment determined by psychological evaluation (5) Patients or family members, able to understand the research plan and willing to participate in this research, and provide written informed consent.

Exclusion criteria

Exclusion criteria: (1) Patients with history of allergy to the active ingredient of parecoxib sodium for injection or any ingredient in excipients, patients with liver and kidney dysfunction, and patients with cardiopulmonary insufficiency. (2) After starting the treatment, after careful distinction, for cases that do not meet the requirements of the design plan or may affect the test results. (3) Cases with poor compliance with the test. (4) People who are dependent on painkillers. (5) The patient has serious adverse reactions or cannot tolerate adverse reactions. (6) Those who withdraw from the experiment before the treatment is over, such as death, automatic discharge, etc.

Design outcomes

Primary

MeasureTime frame
Recovery of bowel function;

Secondary

MeasureTime frame
VAS score;

Countries

China

Contacts

Public ContactAn-Long Zhu

The First Affiliated Hospital of Harbin Medical University

zhuanlone@163.com+86 13504848555

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026